1. Home
  2. APLM vs GV Comparison

APLM vs GV Comparison

Compare APLM & GV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • APLM
  • GV
  • Stock Information
  • Founded
  • APLM 2016
  • GV 2013
  • Country
  • APLM United States
  • GV Canada
  • Employees
  • APLM N/A
  • GV N/A
  • Industry
  • APLM Blank Checks
  • GV Other Consumer Services
  • Sector
  • APLM Finance
  • GV Real Estate
  • Exchange
  • APLM Nasdaq
  • GV Nasdaq
  • Market Cap
  • APLM 15.6M
  • GV 5.8M
  • IPO Year
  • APLM N/A
  • GV 2022
  • Fundamental
  • Price
  • APLM $9.75
  • GV $1.47
  • Analyst Decision
  • APLM Strong Buy
  • GV
  • Analyst Count
  • APLM 2
  • GV 0
  • Target Price
  • APLM $425.00
  • GV N/A
  • AVG Volume (30 Days)
  • APLM 102.2K
  • GV 384.5K
  • Earning Date
  • APLM 02-15-2025
  • GV 12-31-2024
  • Dividend Yield
  • APLM N/A
  • GV N/A
  • EPS Growth
  • APLM N/A
  • GV N/A
  • EPS
  • APLM N/A
  • GV 0.32
  • Revenue
  • APLM $2,101,000.00
  • GV $9,380,985.00
  • Revenue This Year
  • APLM N/A
  • GV N/A
  • Revenue Next Year
  • APLM N/A
  • GV N/A
  • P/E Ratio
  • APLM N/A
  • GV $4.86
  • Revenue Growth
  • APLM 70.54
  • GV 11.25
  • 52 Week Low
  • APLM $6.50
  • GV $1.00
  • 52 Week High
  • APLM $105.00
  • GV $8.85
  • Technical
  • Relative Strength Index (RSI)
  • APLM 50.39
  • GV 45.74
  • Support Level
  • APLM $7.23
  • GV $1.25
  • Resistance Level
  • APLM $8.88
  • GV $3.01
  • Average True Range (ATR)
  • APLM 1.37
  • GV 0.31
  • MACD
  • APLM 0.21
  • GV 0.02
  • Stochastic Oscillator
  • APLM 57.91
  • GV 5.11

About APLM Apollomics Inc.

Apollomics Inc is an innovative clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company lead programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.

About GV Visionary Education Technology Holdings Group Inc.

Visionary Holdings Inc is a private education providing company located in Canada, with subsidiaries in Canada and market partners in China, that offers high-quality education resources to students around the globe. The company aims to provide access to secondary, college, undergraduate and graduate, and vocational education to students in Canada through technological innovation so that more people can learn, grow, and succeed to their full potential. As a fully integrated provider of educational programs and services in Canada, the company has been serving and will continue to serve both Canadian and international students.

Share on Social Networks: